Novel molecular target therapy for pancreatic cancer
| Project/Area Number |
19590317
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
NAKATA Bunzo Osaka City University, 大学院・医学研究科, 准教授 (60271178)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YASHIRO Masakazu 大阪市立大学, 大学院・医学研究科, 准教授 (60305638)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 膵癌 / DNA array / 分子標的治療 / 代謝拮抗剤 |
|---|
| Research Abstract |
There was a positive correlation between the clinical efficacy by gemcitabine and the expression of deoxycytidine kinase in pancreatic cancer. The majority of pancreatic cancers showed overexpression of HER2 and/or EGFR. Consequently, lapatinib, a molecular targeting agent for both of HER2 and EGFR, may be effective for pancreatic cancer. In vitro and in vivo experimental results demonstrated the substantial anti-tumor effect for pancreatic cancer by lapatinib alone and combined with S-1. It was suggested that the anti-tumor effect of lapatinib was associated with HER2 expression.
|
Report
(4 results)
Research Products
(22 results)
